The Current Ratio as of December 2024 (TTM) for Cell Source, Inc. (CLCS) is 0.01

According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.01. This represents a change of -0.22% compared to the average of 0.01 of the last 4 quarters.

Cell Source, Inc. (CLCS) Historical Current Ratio (quarterly & annually)

How has CLCS Current Ratio performed in the past?

The mean historical Current Ratio of Cell Source, Inc. over the last ten years is 0.04. The current 0.01 Current Ratio has changed 3.47% with respect to the historical average. Over the past ten years (40 quarters), CLCS's Current Ratio was at its highest in in the December 2017 quarter at 0.10. The Current Ratio was at its lowest in in the June 2022 quarter at 0.00.

Cell Source, Inc. (CLCS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cell Source, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cell Source, Inc. (CLCS) Average Current Ratio

How has CLCS Current Ratio performed in the past?

The current Current Ratio of Cell Source, Inc. (CLCS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cell Source, Inc. (CLCS) Current Ratio vs. Peers

How is CLCS’s Current Ratio compared to its peers?

Cell Source, Inc.’s Current Ratio is less than Emmaus Life Sciences, Inc. (0.14), greater than Adhera Therapeutics, Inc. (0.00), less than PolarityTE, Inc. (6.41), less than ZIVO Bioscience, Inc. (0.17), less than Pasithea Therapeutics Corp. (14.81), less than Nutriband Inc. (4.96), less than MediciNova, Inc. (16.66), less than Eliem Therapeutics, Inc. (0), less than Panbela Therapeutics, Inc. (0.26), less than Virpax Pharmaceuticals, Inc. (0.13), less than Revelation Biosciences, Inc. (1.64), less than Biodexa Pharmaceuticals Plc (2.16), less than Praxis Precision Medicines, Inc. (10.96), less than Cardio Diagnostics Holdings, Inc. (8.51), less than Sigilon Therapeutics, Inc. (2.40), less than Sonnet BioTherapeutics Holdings, Inc. (0.66), less than ZyVersa Therapeutics, Inc. (33.83), less than X4 Pharmaceuticals, Inc. (4.89), less than eFFECTOR Therapeutics, Inc. (1.03), less than Landos Biopharma, Inc. (4.43), less than Apexigen, Inc. (1.29), less than Navidea Biopharmaceuticals, Inc. (0.56), less than Angion Biomedica Corp. (1.74),

Build a custom stock screener for Cell Source, Inc. (CLCS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cell Source, Inc. (CLCS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.